+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Combined fibrinolysis using reduced-dose alteplase plus abciximab with immediate rescue angioplasty versus primary angioplasty with adjunct use of abciximab for the treatment of acute myocardial infarction: Asia-Pacific Acute Myocardial Infarction Trial (APAMIT) pilot study



Combined fibrinolysis using reduced-dose alteplase plus abciximab with immediate rescue angioplasty versus primary angioplasty with adjunct use of abciximab for the treatment of acute myocardial infarction: Asia-Pacific Acute Myocardial Infarction Trial (APAMIT) pilot study



Catheterization and Cardiovascular Interventions 62(4): 445-452



We conducted a randomized feasibility pilot study comparing combined fibrinolysis with immediate rescue angioplasty vs. primary angioplasty with adjunctive abciximab in patients with acute myocardial infarction (AMI). Seventy patients with ST segment elevation AMI of

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 048580135

Download citation: RISBibTeXText

PMID: 15274152

DOI: 10.1002/ccd.20101


Related references

Thrombin generation and fibrinolytic activities among patients receiving reduced-dose alteplase plus abciximab or undergoing direct angioplasty plus abciximab for acute myocardial infarction. American Journal of Cardiology 89(8): 930-936, April 15, 2002

Angioplasty in acute myocardial infarction after low-dose alteplase and abciximab in transferred patients. A comparison with primary angioplasty on site. Italian Heart Journal 4(5): 311-317, 2003

Gender Differences in Outcomes After Primary Angioplasty Versus Primary Stenting With and Without Abciximab for Acute Myocardial Infarction: Results of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial. Yearbook of Cardiology 2006: 206-208, 2006

Gender differences in outcomes after primary angioplasty versus primary stenting with and without abciximab for acute myocardial infarction: results of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Circulation 111(13): 1611-1618, 2005

Short-term clinical and TIMI 3 flow rate after combined thrombolysis versus primary angioplasty in acute myocardial infarction The Asia-Pacific acute myocardial infarction trial pilot study. American Journal of Cardiology 86(Suppl 8A): 7i, October 16, 2000

Immediate angioplasty versus standard therapy with rescue 3 angioplasty after thrombolysis in the Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction (CARESS-in-AMI): an open, prospective, randomised, multicentre trial. Lancet (North American Edition) 371(9612): 559-568, 2008

Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the controlled abciximab and device investigation to lower late angioplasty complications (CADILLAC) trial. Acc Current Journal Review 13(2): 42-0, 2004

Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Circulation 108(11): 1316-1323, 2003

Efficacy and Safety of a Pharmaco-Invasive Strategy With Half-Dose Alteplase Versus Primary Angioplasty in ST-Segment-Elevation Myocardial Infarction: EARLY-MYO Trial (Early Routine Catheterization After Alteplase Fibrinolysis Versus Primary PCI in Acute ST-Segment-Elevation Myocardial Infarction). Circulation 136(16): 1462-1473, 2017

A prospective, randomized trial comparing primary balloon angioplasty with or without abciximab to primary stenting with or without abciximab in acute myocardial infarction Primary endpoint analysis from the CADILLAC trial. Circulation 102(18 Suppl.): II 664, October 31, 2000

Myocardial salvage after coronary stenting plus abciximab versus fibrinolysis plus abciximab in patients with acute myocardial infarction: a randomised trial. Lancet 359(9310): 920-925, 2002

Effectiveness of early coronary angioplasty and abciximab for failed thrombolysis (reteplase or alteplase) during acute myocardial infarction: (Results from the GUSTO-III trial). American Journal of Cardiology 84(7): 779-784, 1999

Bleeding risks with abciximab after full-dose thrombolysis in rescue or urgent angioplasty for acute myocardial infarction. American Heart Journal 141(2): 218-225, 2001

Effects of pretreatment with abciximab on coronary artery patency and microcirculation in high risk patients with acute myocardial infarction eligible for primary angioplasty Results of the Abciximab Patency Evaluation randomized pilot study. Circulation 102(18 Suppl.): II 774, October 31, 2000

Predictors of and outcomes of early thrombosis following balloon angioplasty versus primary stenting in acute myocardial infarction and usefulness of abciximab (the CADILLAC trial). American Journal of Cardiology 94(8): 983-988, 2004